If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 21

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Selinexor is a medicine that is FDA approved for other cancer but not for endometrial cancer (EC). Selinexor was investigated in a prior study and demonstrated promising activity in a subgroup of patients with TP53 wild-type EC. To date there are no approved treatment options in the maintenance setting for patients with advanced or recurrent EC following response to chemotherapy. In this research study, we will investigate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.
Protocol No